Breast Cancer

Get Email Updates

Resource Centers

Related Checklists

Breast Cancer Guide

DaisyN Guide

Have a question? We're here to help. Ask the Community.

ASK

Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!

New Drug for Advanced Breast Cancer puts Tumor Growth on ‘Pause’

By Lynette Summerill HERWriter
new advanced breast cancer drug pauses tumor growth Auremar/PhotoSpin

Some potentially good news for patients with advanced estrogen receptor-positive (ER+) breast cancer has recently emerged. An experimental drug palbociclib (Pfizer) has shown in stage II clinical trials to significantly increase the length of time without tumor growth while a patient is on treatment.

Patients given palbociclib orally in combination with the standard anti-estrogen treatment, letrozole, experienced no tumor growth for 26.1 months of progression-free survival compared to 7.5 months for those given letrozole alone.

The findings were reported in December 5, 2012 at the CTRC-AACR San Antonio Breast Cancer Symposium by Dr. Richard S. Finn , associate professor of medicine at UCLA’s Jonsson Comprehensive Cancer Center.

The results of the phase II trial were encouraging enough for the drug to recently receive the Food and Drug Administration’s (FDA) “Breakthrough Therapy” designation. This expedites the development and review of potential new medicine for life-threatening diseases or conditions.

The designation, enacted as part of the 2012 FDA Safety and Innovation Act, is given to new drugs which, when administered alone or in combination, demonstrate substantial clinically significant improvement over existing therapies.

Now, researchers at Revlon/UCLA Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center (JCCC) are moving as quickly as safely possible to enrolling patients for a randomized, double-blind phase 3 study at multiple sites. The goal is to evaluate palbociclib combined with letrozole compared to letrozole alone as a first-line treatment for postmenopausal patients with ER positive(+), HER2-negative, locally advanced or metastatic breast cancer.

“This drug combination [has] demonstrated a dramatic and clinically meaningful effect in women with ER+ breast cancer, the most common subtype of breast cancer,” said Finn in an university statement.

Finn said that palbociclib, which is given as a pill, has "very manageable" side effects.

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.

Add a Comment1 Comments

MikeSmith789

Breast cancer became the most common issue in woman specially in a teenager females. The drug palbociclib from pfizer is really interesting and it shown it's effect on it's testing period. The FDA has given a clean chit to this drug and now available for testing. The combination of palbociclib with letrozole shows a drastic effect in woman breast cancer. I hope this research will go more further and will find more effective solution to prevent and to cure from breast cancer.
how to pass a drug test

April 29, 2013 - 10:51am
Image CAPTCHA
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

Improved

1549 Health

Changed

573 Lives

Saved

430 Lives
0 lives impacted in the last 24 hrs Learn More

Take Our Featured Health Poll

Have you been tested for BRCA gene mutation?:
View Results